Choice of replacement fluid dialysate anion in continuous renal replacement therapy

被引:12
|
作者
Macias, WL
机构
[1] INDIANA UNIV,SCH MED,INDIANAPOLIS,IN
[2] ELI LILLY & CO,LILLY LAB CLIN RES,INDIANAPOLIS,IN 46285
关键词
hemofiltration; hemodiafiltration; ARF; dialysis solutions; lactate; bicarbonate; citrate; acetate;
D O I
10.1016/S0272-6386(96)90075-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Normalization of acid-base balance in patients with acute renal failure (ARF) is a primary goal of continuous extracorporeal renal replacement therapy (CRRT). During CRRT, alkali administration, either in the replacement fluid or by diffusive uptake from the dialysate, must replace not only the bicarbonate lost in the buffering of endogenous acid production, but also the bicarbonate lost across the hemodiafilter. In most patients with ARF, a buffer concentration of approximately 30 to 35 mmol/L and an ultrafiltration rate (or dialysate flow rate) approaching or exceeding 1 L/hr can be expected to normalize the acid-base status within 1 to 2 days. In individuals with ARF and lactic acidemia, the buffer load may need to approach greater than or equal to 50 mmol/L to correct the associated metabolic acidemia. Acetate, bicarbonate, citrate, and lactate are the possible choices for bicarbonate or bicarbonate-equivalent administration during CRRT. Acetate- and lactate-based physiologic solutions have the advantage of being commercially available. Under normal conditions, acetate and lactate are metabolized rapidly to bicarbonate. Under conditions where the conversion pathways may be impaired, such as in severe hypoxic or shock states, excessive accumulation of these anions is possible. In the latter situation, the rate of anion conversion to bicarbonate may be slower than the rate of bicarbonate loss across the hemodiafilter, and a worsening of metabolic acidemia may occur. In addition, the administration of large amounts of lactate may result in increased urea generation. Bicarbonate has the major advantage of being the most physiologic anion. Unfortunately, the production of a commercially available bicarbonate-based physiologic solution is difficult because of the loss of bicarbonate from the solution or the formation of calcium and magnesium salts. The use of citrate as an anticoagulant obviates the need for additional alkali because citrate is metabolized to bicarbonate. Excessive citrate accumulation is rare, even in the setting of severe hepatic failure. (C) 1996 by the National Kidney Foundation, Inc.
引用
收藏
页码:S15 / S20
页数:6
相关论文
共 50 条
  • [1] THE OPTIMAL TEMPERATURE FOR REPLACEMENT FLUID AND DIALYSATE IN CONTINUOUS RENAL REPLACEMENT THERAPY: A RANDOMIZED, CONTROLLED STUDY
    Pooprasert, Thitipong
    Vongsanim, Surachet
    Noppakun, Kajohnsak
    [J]. NEPHROLOGY, 2020, 25 : 38 - 38
  • [2] BICARBONATE DIALYSATE FOR CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)
    LEBLANC, M
    MORENO, L
    ROBINSON, O
    TAPOLYAI, M
    PAGANINI, EP
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 497 - 497
  • [3] Fluid management in continuous renal replacement therapy
    Mehta, RL
    [J]. SEMINARS IN DIALYSIS, 1996, 9 (02) : 140 - 144
  • [4] Fluid Management on Continuous Renal Replacement Therapy
    Murugan, Raghavan
    Kellum, John A.
    [J]. 40 YEARS OF CONTINUOUS RENAL REPLACEMENT THERAPY, 2018, 194 : 60 - 69
  • [5] CYCLOHEXANONE IS PRESENT IN PERITONEAL DIALYSATE AND CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS
    King, Joshua
    Gordon-Cappitelli, Judit
    Santhanam, Lakshmi
    Shoukas, Artin
    Fine, Derek
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (05) : A68 - A68
  • [6] Validation of a low-cost continuous renal replacement therapy dialysate fluid controller for experimental purposes
    dos Santos, Yuri de Albuquerque Pessoa
    Park, Viviane Flor
    Cardozo Junior, Luis Carlos Maia
    Besen, Bruno Adler Maccagnan Pinheiro
    Mendes, Pedro Vitale
    Park, Marcelo
    [J]. INTENSIVE CARE MEDICINE EXPERIMENTAL, 2024, 12 (01)
  • [7] Validation of a low-cost continuous renal replacement therapy dialysate fluid controller for experimental purposes
    Yuri de Albuquerque Pessoa dos Santos
    Viviane Flor Park
    Luis Carlos Maia Cardozo Junior
    Bruno Adler Maccagnan Pinheiro Besen
    Pedro Vitale Mendes
    Marcelo Park
    [J]. Intensive Care Medicine Experimental, 12
  • [9] BICARBONATE REPLACEMENT FLUID WITH CONTINUOUS RENAL REPLACEMENT THERAPY IN CRITICALLY ILL ADULTS
    Kram, Bridgette
    Mueller, Kelsey
    Tiemann, Andrew
    Musgrove, John
    Kram, Shawn
    [J]. CRITICAL CARE MEDICINE, 2023, 51 (01) : 540 - 540
  • [10] Precision Fluid Management in Continuous Renal Replacement Therapy
    Murugan, Raghavan
    Hoste, Eric
    Mehta, Ravindra L.
    Samoni, Sara
    Ding, Xiaoqiang
    Rosner, Mitchell H.
    Kellum, John A.
    Ronco, Claudio
    [J]. BLOOD PURIFICATION, 2016, 42 (03) : 266 - 278